Baird Medical to Attend Microcap Conference at Borgata Hotel
Baird Medical (NASDAQ: BDMD), a pioneer in microwave ablation technology (MWA), has announced its participation in the upcoming Microcap Conference at the Borgata Hotel, Atlantic City, from January 28-30, 2025. The company, which specializes in developing advanced needles and apparatus for thyroid nodule microwave ablation, offers a minimally invasive alternative to traditional open neck surgery.
Following their FDA 510(k) clearance in November 2023 and with an established market leadership in China, Baird Medical is strategically positioned for global expansion. Chairwoman Haimei Wu emphasized the significance of their FDA clearance and the opportunity to showcase their innovations at the conference.
The annual Microcap Conference will feature company presentations and one-on-one meetings with investors. Interested parties can schedule meetings by contacting maxm@bairdmed.com.
Baird Medical (NASDAQ: BDMD), un pioniere nella tecnologia di ablazione a microonde (MWA), ha annunciato la sua partecipazione alla prossima Microcap Conference presso il Borgata Hotel, Atlantic City, dal 28 al 30 gennaio 2025. L'azienda, specializzata nello sviluppo di aghi avanzati e apparecchiature per l'ablazione a microonde dei noduli tiroidei, offre un'alternativa minimamente invasiva alla tradizionale chirurgia aperta al collo.
Dopo aver ottenuto l'approvazione 510(k) dalla FDA nel novembre 2023 e con una leadership di mercato consolidata in Cina, Baird Medical è strategicamente posizionata per un'espansione globale. La presidente Haimei Wu ha sottolineato l'importanza della loro approvazione FDA e l'opportunità di mostrare le loro innovazioni durante la conferenza.
La Microcap Conference annuale presenterà presentazioni aziendali e incontri individuali con gli investitori. Le parti interessate possono programmare incontri contattando maxm@bairdmed.com.
Baird Medical (NASDAQ: BDMD), un pionero en la tecnología de ablación por microondas (MWA), ha anunciado su participación en la próxima Microcap Conference en el Borgata Hotel, Atlantic City, del 28 al 30 de enero de 2025. La compañía, que se especializa en el desarrollo de agujas avanzadas y aparatos para la ablación de nódulos tiroideos por microondas, ofrece una alternativa mínimamente invasiva a la cirugía abierta tradicional en el cuello.
Tras obtener la aprobación 510(k) de la FDA en noviembre de 2023 y con un liderazgo de mercado establecido en China, Baird Medical está estratégicamente posicionada para una expansión global. La presidenta Haimei Wu enfatizó la importancia de su aprobación por la FDA y la oportunidad de mostrar sus innovaciones en la conferencia.
La Microcap Conference anual contará con presentaciones de empresas y reuniones individuales con inversionistas. Las partes interesadas pueden programar reuniones contactando maxm@bairdmed.com.
Baird Medical (NASDAQ: BDMD)는 마이크로웨이브 절제 기술 (MWA)의 선두 주자로, 2025년 1월 28일부터 30일까지 애틀랜틱 시티의 보르가타 호텔에서 열리는 마이크로캡 컨퍼런스에 참가한다고 발표했습니다. 갑상선 결절의 마이크로웨이브 절제를 위한 첨단 바늘 및 장비 개발에 전문화된 이 회사는 전통적인 개복 수술에 대한 최소 침습적인 대안을 제공합니다.
2023년 11월 FDA 510(k) 승인 후, 중국에서 확고한 시장 리더십을 확보한 Baird Medical은 글로벌 확장을 위해 전략적으로 자리잡고 있습니다. 회장 Haimei Wu는 FDA 승인의 중요성과 컨퍼런스에서 혁신을 선보일 기회에 대해 강조했습니다.
연례 마이크로캡 컨퍼런스에서는 기업 발표와 투자자와의 일대일 미팅이 진행됩니다. 관심이 있는 분들은 maxm@bairdmed.com으로 연락하여 미팅을 예약할 수 있습니다.
Baird Medical (NASDAQ: BDMD), un pionnier dans la technologie d'ablation par micro-ondes (MWA), a annoncé sa participation à la prochaine Microcap Conference qui se tiendra à l'hôtel Borgata, Atlantic City, du 28 au 30 janvier 2025. L'entreprise, spécialisée dans le développement d'aiguilles avancées et d'appareils pour l'ablation par micro-ondes des nodules thyroïdiens, offre une alternative peu invasive à la chirurgie conventionnelle du cou.
Suite à leur approbation 510(k) par la FDA en novembre 2023 et avec une position de leader sur le marché en Chine, Baird Medical est stratégiquement positionnée pour une expansion mondiale. La présidente Haimei Wu a souligné l'importance de leur approbation FDA et l'opportunité de présenter leurs innovations lors de la conférence.
La Microcap Conference annuelle comprendra des présentations d'entreprises et des rencontres individuelles avec des investisseurs. Les parties intéressées peuvent programmer des réunions en contactant maxm@bairdmed.com.
Baird Medical (NASDAQ: BDMD), ein Pionier in der Mikrowellenablationstechnologie (MWA), hat seine Teilnahme an der bevorstehenden Microcap Conference im Borgata Hotel in Atlantic City vom 28. bis 30. Januar 2025 bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung fortschrittlicher Nadeln und Apparate zur Mikrowellenablation von Schilddrüsenknoten spezialisiert hat, bietet eine minimalinvasive Alternative zur herkömmlichen offenen Halsoperation.
Nach der FDA 510(k) Genehmigung im November 2023 und mit einer etablierten Marktführerschaft in China ist Baird Medical strategisch auf globale Expansion vorbereitet. Vorsitzende Haimei Wu betonte die Bedeutung ihrer FDA-Genehmigung und die Gelegenheit, ihre Innovationen auf der Konferenz zu präsentieren.
Die jährliche Microcap Conference wird Unternehmenspräsentationen und Einzelgespräche mit Investoren umfassen. Interessierte Parteien können Meetings vereinbaren, indem sie maxm@bairdmed.com kontaktieren.
- None.
- None.
Baird Medical specializes in the design and development of cutting-edge needles and apparatus for microwave ablation of thyroid nodules. This minimally invasive treatment is an alternative to traditional open neck surgery and offers significant benefits for patients worldwide. With a dominant market presence in
"We are excited to connect with investors and industry peers at the Microcap Conference," said Haimei Wu, Chairwoman of Baird Medical. "Our recent FDA clearance represents a pivotal milestone, enabling us to bring our innovative solutions to patients in
The Microcap Conference is an annual gathering of microcap company executives, institutional investors, and thought leaders. It offers a dynamic forum for networking, presentations, and discussions about emerging investment opportunities. Baird Medical's leadership team will deliver presentations and engage in one-on-one meetings with investors throughout the week.
Attendees and interested parties are encouraged to visit Baird Medical's booth or schedule a meeting by contacting maxm@bairdmed.com.
For additional information about Baird Medical and its innovative microwave ablation technology, please visit https://bairdmed.com/.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-attend-microcap-conference-at-borgata-hotel-302356624.html
SOURCE BDMD
FAQ
What is the significance of BDMD's FDA 510(k) clearance received in November 2023?
When and where is Baird Medical (BDMD) presenting at the Microcap Conference 2025?
What is BDMD's primary medical technology and its benefits?
How can investors schedule meetings with BDMD at the 2025 Microcap Conference?
What markets does BDMD currently operate in?
